Related Experiment Videos
Follow-up on primary prevention trials
1Department of Internal Medicine, University of Cape Town Medical School, Republic of South Africa. dmarias@uctgshl.uct.ac.za
Insights
Primary prevention trials show cardiovascular benefits without increased mortality. Selective, cost-effective LDL cholesterol reduction is key for high-risk patients, suggesting targeted interventions for coronary artery disease.
Area of Science:
- Cardiovascular disease prevention
- Lipid management
Background:
- Primary prevention trials demonstrate cardiovascular benefits of lipid-lowering therapies.
- These benefits are observed without adverse effects on overall mortality or morbidity in broad patient cohorts.
Purpose of the Study:
- To analyze the effectiveness of LDL cholesterol reduction in primary prevention of coronary artery disease.
- To evaluate the cost-effectiveness of targeted lipid-modifying drug management in high-risk individuals.
Main Methods:
- Analysis of data from primary prevention trials, including the West of Scotland Coronary Prevention Study and the Air Force/Texas Coronary Artery Prevention Study.
- Evaluation of LDL cholesterol reduction thresholds and cost-effectiveness of interventions.
Main Results:
- A 25% reduction in LDL cholesterol is associated with cardiovascular benefits.
- Effective treatment is achievable and cost-effective in selected high-risk individuals.
- Benefits are observed even at lower plasma lipid concentrations.
Conclusions:
- Current lifestyle and drug management are successful in primary prevention.
- Selective, cost-effective treatment is recommended for very high-risk individuals.
- Future research should focus on specific at-risk cohorts, targeted therapies, and additional risk factors.
Abstract:
Recent primary prevention trials demonstrated that cardiovascular morbidity and mortality benefits are not accompanied by adverse effects on overall mortality and morbidity in cohorts representing plasma cholesterol concentrations observed in the bulk of coronary artery disease. During the past year, further analyses of the West of Scotland Coronary Prevention Study have indicated that benefit requires a 25% reduction of LDL cholesterol and that such treatment is not very expensive when focussed on selected high-risk individuals. The Air Force/Texas Coronary Artery Prevention Study indicated that benefit is seen in individuals with even lower plasma lipid concentration. Although current treatment with lifestyle and lipid modifying drug management is successful in primary prevention, the unpredictable nature of coronary artery disease and the cost of drugs mitigate against direct application of drug management in persons with relatively low risk, but selective treatment should be undertaken in very high-risk settings. Future studies need to examine more specific at risk cohorts, test better targeted lipoprotein modification, test more risk factors and also examine whether changes in vascular function or markers of inflammation will predict a better outcome.